Gabapentin Prescriptions Double Across US as Doctors Seek Safer Pain and Sleep Options

As gabapentin quietly becomes one of America’s — and New York City’s — most prescribed drugs, questions abound about the trade-offs between greater access and uncertain risks.

In the city that never sleeps (though many wish they could), a pill originally designed for epileptics now nestles in millions of bathroom cabinets. Gabapentin, once a niche treatment for seizures and shingles-related nerve pain, has metamorphosed into one of the most common prescriptions dispensed across New York City’s pharmacies. If its trajectory in the United States is a guide, its presence is set only to burgeon: between 2013 and 2022, national gabapentin prescriptions more than doubled, swelling from 8.3 million to a staggering 17 million, according to Medicare data.

The news event, then, is not a sudden scandal or courtroom drama, but a dramatic shift quietly pervading medical practice: gabapentin is now being given for ailments ranging from back pain to anxiety and insomnia. What was once a medication reserved for neuralgic pain and refractory epilepsy has, through a flurry of “off-label” prescribing, entered the mainstream of primary care. New Yorkers seeking respite from chronic aches, fretful nights, or persistent nerves increasingly encounter this drug not as a last resort, but as a first-line fix.

For the city’s physicians and policymakers, this surge is fraught with practical consequences. Gabapentin, unlike opioids or benzodiazepines, is not yet a controlled substance in New York State. Its reputation as an alternative with fewer stigma-laced baggage has made it attractive to overburdened prescribers trying to avoid the next addiction crisis. At the neighbourhood health centre or urgent care chain, the calculus is clear: faced with a patient in discomfort, it seems a palatable, low-cost compromise between doing too little and risking too much.

But the proliferation also brings less palatable corollaries. Though gabapentin’s side effects are generally milder than those of opioids, its efficacy for everyday complaints is less than miraculous. Meta-analyses suggest only modest benefits for many conditions beyond its original indications. And yet, patients — often those from communities hit hardest by the opioid epidemic, including parts of the Bronx and eastern Brooklyn — now greet it as the pill for almost anything. This bodes imperfectly for New York’s already fragmented system of chronic care, possibly substituting one set of pharmacological unknowns for another.

There are economic ramifications, too. As prescriptions have multiplied, so has spending: though available generically, gabapentin now commands a significant share of Medicaid and private insurance outlays for pain and anxiety. The brisk trade is a boon for manufacturers of generics, but a point of acute discomfort for those monitoring the city’s healthcare budget. Insurers, alert to well-trodden patterns of overuse, are already scrutinising claims, seeking evidence that the flood of prescriptions aligns with best practices.

On a societal level, the rise of gabapentin reflects evolving medical mores. After decades of pain undertreatment, the opioid crisis upended assumptions, leaving clinicians eager — perhaps too eager — to switch to options perceived as “safer.” In practice, this has fuelled a kind of therapeutic whack-a-mole, with gabapentin now occupying some of the space vacated by more tightly regulated drugs. This pattern, while understandable, carries risk; recent case studies from New York and elsewhere note increasing reports of dependence, misuse, and — when combined with other depressants — even fatal overdoses.

Nor is New York alone. Across the country, gabapentin has steadily climbed the charts of most-dispensed medications. In states like Kentucky and West Virginia, authorities have gone so far as to add it to lists of controlled substances in response to surging misuse. It is a fate that could soon await New York. Internationally, the pattern repeats with local flavour: Britain in 2019 reclassified gabapentin as a Class C controlled drug after noticing a similar uptick in deaths involving the medication.

Balancing access, vigilance, and evidence

The real question is not whether gabapentin “deserves” its popularity, but whether the American — and New York — approach to prescribing it bodes well for public health. Evidence for its effectiveness outside epilepsy and neuropathic pain is tepid. Its appeal lies partly in the absence of better, simpler remedies for pain, sleep, and anxiety. But this is hardly a glowing endorsement; in chasing quick pharmaceutical solutions, the city risks neglecting longer-term, harder-won gains in preventive and mental health care.

In the warren of Gotham’s clinics and emergency rooms, the proliferation of gabapentin is a symptom as much as a remedy. Patients want immediate relief. Clinicians, incentivised by algorithmic medicine and electronic records, can clock up prescriptions at pace. In theory, all prescribing must flow from careful weighing of risks and benefits. In practice, busy providers sometimes reach for what is simply “good enough,” particularly when alternatives are more expensive, less accessible, or more politically fraught.

Reports of patients unclear on why they are taking gabapentin, or for how long, bode ill for adherence, safety, and outcomes. As with any widely used medicine, the cumulative risks — accidental misuse, confusing side effects, gradual dependence — only become glaring with scale. New York, trailing some of its more quick-reacting peers, has so far resisted classifying gabapentin as a controlled substance; but that stance may not be tenable as reports of misuse accrue.

The city’s health authorities would do well to refrain from the panicky swings that have repeatedly characterised American drug policy. Neither laissez-faire prescribing nor blanket restrictions will serve New Yorkers well. Instead, robust surveillance, prescriber education, and rigorous application of evidence-based guidelines ought to keep risks at bay without denying genuine sufferers access to a useful drug.

The modern history of pharmacy is littered with once-benign remedies repurposed — and sometimes repented — multiple times. Gabapentin’s present vogue in New York City is less a revolution than a harbinger of the intractabilities of urban health: chronic pain, interrupted sleep, uneasy minds. It is neither cure-all nor menace, but another chapter in the city’s delicate negotiation between hope and harm. ■